Shocker of a day all round for the ASX, no doubt AHZ has been caught up with it too. The silver lining is that the lower currency will increase revenue from growing sales of Cardiocel.
Key announcements to look forward to for the rest of the calender year/financial year:
(1) Completion of recruitment for the HSV 2 vaccine trial
(2) Increased centre uptake of Cardiocel and increased sales
(3) Increased applicationds of Adapt for other tissue types
(4)Positive vaccine trial results
(5) Vaccine partnership
Also at the AGM, a path to profitability. Keep pressure on management to deliver this.
Best Company for Future, page-6
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
0.000(0.00%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.80 | $96.66K | 9.794K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 286 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.99 | 198 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |